Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Neuro-Ophthalmology (Aeolus Press)|December 22, 2022
Application of the International Interocular Difference Thresholds into Practice: Localising the Patient ExperiencePeter V Sguigna, Lauren M Tardo, Kyle M Blackburn, et al.
Frontiers in Neurology|November 28, 2022
APDM gait and balance measures fail to predict symptom progression rate in Parkinson's diseaseD Campbell Dewey, Shilpa Chitnis, Morgan C McCreary, et al.
Behavioural Brain Research|September 15, 2012
A novel highly selective 5-HT6 receptor antagonist attenuates ethanol and nicotine seeking but does not affect inhibitory response control in Wistar ratsN M W J de Bruin, A C McCreary, A van Loevezijn, et al.
AJNR. American Journal of Neuroradiology|April 24, 2026
Longitudinal Cortical Surface Signatures Distinguish Neuromyelitis Optica Spectrum Disorder from Multiple SclerosisDarin T Okuda, Thomas A Stanley, Morgan C McCreary, et al.
Multiple Sclerosis and Related Disorders|November 16, 2025
Why the disease modifying therapy transition? Investigating the reasons and clinical consequences in multiple sclerosisDarin T Okuda, Tom G Punnen, Tatum M Moog, et al.
Journal of Thrombosis and Haemostasis : JTH|March 2, 2023
A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasmaViola J F Strijbis, Lorenzo G R Romano, Ka Lei Cheung, et al.
Synapse (New York, N.Y.)|September 27, 2006
In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonistJeffrey C Glennon, Guus Van Scharrenburg, Eric Ronken, et al.
Neurology and Therapy|June 27, 2026
Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from PseudoexacerbationDarin T Okuda, Tatum M Moog, Morgan C McCreary, et al.
Bioorganic & Medicinal Chemistry Letters|September 6, 2005
Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicityJos H M Lange, Herman H van Stuivenberg, Willem Veerman, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibitionRolf van Hes, Pieter Smid, Cees N J Stroomer, et al.
Pageof 13